Table 2.
Results of univariate logistic regressions of potential factors favoring the first biopsy-proven acute rejection (BPAR)
| Covariate | Category | OR (95%CI) | p |
|---|---|---|---|
| CDEC-MPS* (mg* month) | Per unit increase | 0.999 (0.997,1.001) | 0.708 |
|
| |||
| Cyclosporine AUCC2** (mg* month/L) | Per unit increase | 1.000 (0.999,1.001) | 0.594 |
|
| |||
| Age | Per year increase | 0.99 (0.96,1.02) | 0.542 |
|
| |||
| Sex | M vs. F | 1.22 (0.61,2.47) | 0.571 |
|
| |||
| Randomization group | with vs. without steroids | 0.98 (0.5,1.93) | 0.951 |
|
| |||
|
IMPDH2 IVS7+10 T>C (rs11706052) |
TT vs TC/CC | 1.35 (0.56,3.24) | 0.501 |
|
| |||
| IMPDH1 C>T (rs2278923) | CT vs. CC | 0.94 (0.43,2.06) | 0.883 |
| TT vs. CC | 0.87 (0.33,2.30) | 0.772 | |
|
| |||
| IMPDH1 C>T (rs2278924) | CT vs. CC | 0.83 (0.4,1.7) | 0.606 |
| TT vs. CC | 0.94 (0.3,2.93) | 0.910 | |
|
| |||
| ABCC2 -24 C>T (rs717620) | CT vs. CC | 0.95 (0.46,1.92) | 0.877 |
|
| |||
| ABCC2 1249 G>A (rs2273697) | GG vs. GA/AA | 1.65 (0.79,3.44) | 0.185 |
|
| |||
| ABCC2 3972 C>T (rs3740066) | CT vs. CC | 1.36 (0.63,2.97) | 0.434 |
| TT vs. CC | 2.31 (0.88,6.05) | 0.088 | |
|
| |||
| ABCC2 4544 G>A (rs8187710) | GG vs. GA/AA | 1.39 (0.52,3.69) | 0.513 |
|
| |||
| SLCO1B3 334 T>G (rs4149117) | TG/TT vs. GG | 0.75 (0.34,1.64) | 0.472 |
|
| |||
| UGT1A8 518 C>G (rs1042597) | CG/GG vs. CC | 1.04 (0.52,2.05) | 0.920 |
|
| |||
| UGT1A9 -2152 C>T (rs17868320) | CC vs. CT | 1.36 (0.39,4.74) | 0.632 |
|
| |||
| UGT1A9 -275 T>A | TT vs. TA/AA | 0.55 (0.20,1.52) | 0.252 |
|
| |||
| UGT2B7 -840 G>A (rs7438135) | GA vs. AA | 1.54 (0.7,3.41) | 0.282 |
| GG vs. AA | 0.89 (0.34,2.33) | 0.808 | |
|
| |||
|
CYP2C8 G>A rs11572076 |
GG vs. GA | 0.37 (0.02,6.07) | 0.488 |
|
| |||
|
HUS1 G>A rs1056663 |
GA vs. AA | 1.15 (0.46,2.83) | 0.767 |
| GG vs. AA | 1.35 (0.52,3.49) | 0.542 | |
|
| |||
| IL12A G>A rs568408 |
GG vs. GA/AA | 0.66 (0.29,1.51) | 0.326 |
*
(mean EC-MPS dose)×the follow-up period duration;
**
(mean C2)×follow-up duration